Xilio Therapeutics Inc (XLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 12,648 | 13,686 | 19,066 | 8,084 | 2,930 |
| Gross Profit | 12,648 | 13,686 | 19,066 | 8,084 | 2,930 |
| Operating Expenses | 26,760 | 25,522 | 20,995 | 22,450 | 16,781 |
| Operating Income | -14,112 | -11,836 | -1,929 | -14,366 | -13,851 |
| Other Income | 4,583 | 22,196 | -14,358 | -1,478 | 586 |
| Pre-tax Income | -9,529 | 10,360 | -16,287 | -15,844 | -13,265 |
| Net Income Continuous | -9,529 | 10,360 | -16,287 | -15,844 | -13,265 |
| Net Income | $-9,529 | $10,360 | $-16,287 | $-15,844 | $-13,265 |
| EPS Basic Total Ops | -0.58 | 2.08 | -1.54 | -2.24 | -2.49 |
| EPS Basic Continuous Ops | -0.58 | 2.18 | -1.58 | -2.30 | -2.49 |
| EPS Diluted Total Ops | -0.58 | 2.08 | -1.54 | -2.24 | -2.49 |
| EPS Diluted Continuous Ops | -0.58 | 2.18 | -1.58 | -2.30 | -2.49 |
| EPS Diluted Before Non-Recurring Items | -0.58 | -0.85 | -0.42 | -2.24 | -2.52 |
| EBITDA(a) | $-13,768 | $-11,513 | $-1,589 | $-13,985 | $-13,354 |